AU8349101A - Macrolide formulations for inhalation and methods of treatment of endobronchial infections - Google Patents

Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Info

Publication number
AU8349101A
AU8349101A AU8349101A AU8349101A AU8349101A AU 8349101 A AU8349101 A AU 8349101A AU 8349101 A AU8349101 A AU 8349101A AU 8349101 A AU8349101 A AU 8349101A AU 8349101 A AU8349101 A AU 8349101A
Authority
AU
Australia
Prior art keywords
inhalation
treatment
methods
endobronchial infections
macrolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU8349101A
Other languages
English (en)
Inventor
William R Baker
Peter B Challoner
Ribhi M Shawar
Kay K Huh
David M Rycman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU8349101A publication Critical patent/AU8349101A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU8349101A 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections Pending AU8349101A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21703200P 2000-07-10 2000-07-10
PCT/US2001/041328 WO2002003998A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Publications (1)

Publication Number Publication Date
AU8349101A true AU8349101A (en) 2002-01-21

Family

ID=22809403

Family Applications (2)

Application Number Title Priority Date Filing Date
AU8349101A Pending AU8349101A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2001283491A Ceased AU2001283491B2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001283491A Ceased AU2001283491B2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Country Status (11)

Country Link
EP (1) EP1309332A2 (xx)
JP (1) JP2004502736A (xx)
KR (1) KR20030020924A (xx)
CN (1) CN1202831C (xx)
AU (2) AU8349101A (xx)
BR (1) BR0112330A (xx)
CA (1) CA2415498A1 (xx)
IL (1) IL153875A0 (xx)
MX (1) MXPA03000321A (xx)
NZ (1) NZ523693A (xx)
WO (1) WO2002003998A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
WO2004075874A1 (en) * 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
CA2528841A1 (en) * 2003-06-10 2004-12-23 Astellas Pharma Inc. Aerosol preparation comprising enclosure enclosing aerosol composition containing macrolide compound
US20050266578A1 (en) * 2004-05-06 2005-12-01 Gruenke Larry D Methods and systems for detection of macrolides
PL2316419T3 (pl) 2004-05-17 2012-12-31 Gilead Sciences Inc Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia bakteryjnych infekcji dróg oddechowych
ES2666276T3 (es) 2006-10-11 2018-05-03 Laboratoires Smb Sa Composición farmacéutica antiinfecciosa para inhalación
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
ES2565083T3 (es) 2008-10-24 2016-03-31 Cempra Pharmaceuticals, Inc. Biodefensas usando macrólidos que contienen triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN109091489A (zh) * 2010-03-10 2018-12-28 森普拉制药公司 大环内酯类抗生素的肠胃外制剂
RU2608390C2 (ru) 2010-05-20 2017-01-18 Семпра Фармасьютикалз, Инк. Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
JP6426696B2 (ja) * 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr FORMULATION
CN114796116A (zh) * 2022-05-17 2022-07-29 中山大学附属第六医院 一种阿奇霉素吸入剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60209517A (ja) * 1984-04-03 1985-10-22 Unitika Ltd エアゾ−ル組成物
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
JPH01283225A (ja) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd 牛呼吸器感染症治療用エアゾール製剤およびそれを用いる治療方法
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
AU1299095A (en) * 1993-12-02 1995-06-19 Cytrx Corporation Antiinfective compositions and methods of use
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
CA2153553A1 (en) * 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
DE19518917A1 (de) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmed Stabile, konzentrierte lokalverträgliche Erythromycylamin-Lösungen
EP1019023B1 (en) * 1997-09-29 2003-05-07 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
EA200100289A1 (ru) * 1998-08-28 2001-10-22 Эли Лилли Энд Компани Способ введения инсулинотропных пептидов
AU5528299A (en) * 1998-09-15 2000-04-03 Naeja Pharmaceutical Inc. Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
EP1161247A4 (en) * 1998-12-17 2002-05-15 Chiron Corp Treatment method for severe chronic bronchitis (bronchiectasis) using an antibiotic aerosol
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Also Published As

Publication number Publication date
NZ523693A (en) 2004-08-27
JP2004502736A (ja) 2004-01-29
IL153875A0 (en) 2003-07-31
KR20030020924A (ko) 2003-03-10
BR0112330A (pt) 2003-10-07
CN1471401A (zh) 2004-01-28
AU2001283491B2 (en) 2007-02-15
CA2415498A1 (en) 2002-01-17
EP1309332A2 (en) 2003-05-14
CN1202831C (zh) 2005-05-25
MXPA03000321A (es) 2003-06-06
WO2002003998A3 (en) 2002-06-13
WO2002003998A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU8349101A (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
HUP0400477A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001280702A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
EP1365686A4 (en) METHOD AND SYSTEM FOR ENDOSCOPIC TARGETING
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
IL145282A0 (en) Compositions and methods for treatment of staphylococcal infection
AU5114000A (en) P43 anti-tumor therapeutic agent and three dimensional structure of its cytokinedomain
IL162689A0 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
PL369725A1 (en) Pharmaceutical formulations containing low concentration of peroxide for treating or preventing vaginal infections
IL159585A0 (en) Single dose azithromycin for treating respiratory infections
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
EP1351699A4 (en) METHOD FOR IMPROVED DIAGNOSIS AND TREATMENT OF MYCOBACTERIAL INFECTIONS
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
GB0025556D0 (en) Treatment and prophylaxis of disease and infections of pigs and poultry
AU1646701A (en) Composition for treating respiratory tract infections
IL159296A0 (en) Lactone formulations and method of use
AP2002002432A0 (en) Treatment of viral infections
IL155819A0 (en) Methods of treatment comprising administration of substance p
AU2002220584A1 (en) Use of lipopeptides or lipoproteins for treating lung infections and lung tumours
AU2001267177A1 (en) Diagnosis and treatment of herpes infections
HUP0200466A2 (en) Lipoglycan compositions and methods of treating parasitic infections
EP1303281A4 (en) METHODS OF TREATMENT
AU5806001A (en) Compositions and methods for treatment of mucosal infections